Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome

Immunologic Research

Volumn 64, Issue 2, 2016, Pages 489-496

  Wang, Juan ^a   Peng, Huiyong ^a   Tian, Jie ^a   Ma, Jie ^a   Tang, Xinyi ^a   Rui, Ke ^a   Tian, Xinyu ^a   Wang, Yungang ^a   Chen, Jianguo ^a   Lu, Liwei ^b   Xu, Huaxi ^a   Wang, Shengjun ^a  

^a JIANGSU UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Long noncoding RNA; Sj gren syndrome; T helper type 1 cells; TMEVPG1

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; LONG UNTRANSLATED RNA; SSA PROTEIN; TMEVPG1 PROTEIN; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PRIORITY JOURNAL; SJOEGREN SYNDROME; TH1 CELL; UPREGULATION; AGED; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RNA, LONG NONCODING; SJOGREN'S SYNDROME; TH1 CELLS; UP-REGULATION;

EID: 84961150608     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8715-4     Document Type: Article

References (35)

1. Singh N, Cohen PL. The T cell in Sjögren’s syndrome: force majeure, not spectateur. J Autoimmun. 2012;39(3):229–33.
2. Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjögren’s syndrome. J Immunol. 1994;152:5532–9.
3. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren’s syndrome. Br J Rheumatol. 1995;34:326–33.
4. Kolkowski EC, Reth P, Pelusa F, et al. Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjögren’s syndrome. J Autoimmun. 1999;13(1):155–62.
5. Li X, Xu B, Wang Y, et al. Anti-inflammatory effect of peroxisome proliferator-activated receptor-γ (PPAR-γ) on non-obese diabetic mice with Sjögren’s syndrome. Int J Clin Exp Pathol. 2014;7(8):4886–94.
6. Cha S, Brayer J, Gao J, et al. A dual role for interferon-gamma in the pathogenesis of Sjögren’s syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol. 2004;60(6):552–65.
7. Lin X, Rui K, Deng J, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann Rheum Dis. 2015;74(6):1302–10.
8. Peng H, Liu Y, Tian J, et al. Decreased expression of microRNA-125a-3p upregulates interleukin-23 receptor in patients with Hashimoto’s thyroiditis. Immunol Res. 2015;62(2):129–36.
9. + T cells in the pathogenesis of Graves’ disease. Endocrine. 2015;49(3):752–60.
10. Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjögren syndrome and its functional role in innate immunity. Eur J Immunol. 2011;41(7):2029–39.
11. Spierings DC, McGoldrick D, Hamilton-Easton AM, et al. Ordered progression of stage-specific miRNA profiles in the mouse B2 B-cell lineage. Blood. 2011;117(20):5340–9.
12. Chiyomaru T, Fukuhara S, Saini S, et al. Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells. J Biol Chem. 2014;289(18):12550–65.
13. Van Roosbroeck K, Pollet J, Calin GA. MiRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013;13(2):183–204.
14. Mourtada-Maarabouni M, Hasan AM, Farzaneh F, et al. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol. 2010;78(1):19–28.
15. Gomez JA, Wapinski OL, Yang YW, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell. 2013;152(4):743–54.
16. Collier SP, Collins PL, Williams CL, et al. Cutting edge: influence of TMEVPG1, a long intergenic noncoding RNA, on the expression of Ifng by Th1 cells. J Immunol. 2012;189(5):2084–8.
17. Collier SP, Henderson MA, Tossberg JT, et al. Regulation of the Th1 genomic locus from Ifn-g. through Tmevpg1 by T-bet. J Immunol. 2014;193(8):3959–65.
18. Jonsson R, Vogelsang P, Volchenkov R, et al. The complexity of Sjögren’s syndrome: novel aspects on pathogenesis. Immunol Lett. 2011;141(1):1–9.
19. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American- European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
20. Vasudevan A, Bhide PG. Angiogenesis in the embryonic CNS: a new twist on an old tale. Cell Adh Migr. 2008;2(3):167–9.
21. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sjögren’s syndrome. Autoimmun Rev. 2011;10(3):123–5.
22. Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009;106(28):11667–72.
23. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.
24. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006; 15 Spec No 1:R17-29.
25. Jimenez SA, Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren syndrome. Autoimmun Rev. 2013;12(11):1046–51.
26. Vigneau S, Rohrlich PS, Brahic M, et al. Tmevpg1, a candidate gene for the control of Theiler’s virus persistence, could be implicated in the regulation of gamma interferon. J Virol. 2003;77(10):5632–8.
27. Gonzalez-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125–35.
28. Li H, Ice JA, Lessard CJ, et al. Interferons in Sjögren’s syndrome: genes, mechanisms, and effects. Front Immunol. 2013;4:290.
29. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52(5):1534–44.
30. Hall JC, Baer AN, Shah AA, et al. Molecular subsetting of interferon pathways in Sjögren’s syndrome. Arthriti Rheumatol. 2015;67(9):2437–46.
31. Nguyen CQ, Peck AB. The interferon-signature of Sjögren’s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol. 2013;4:142.
32. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci USA. 2012;109(43):17609–14.
33. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res. 2011;31(1):5–11.
34. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjögren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjögren’s related lymphomagenesis. J Autoimmun. 2015;S0896–8411(15):30006–8.
35. Ogawa N, Li P, Li Z, et al. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren’s syndrome. Arthritis Rheum. 2002;46:2730–41.